All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Jaktinib, a Janus kinase, and activin A receptor type I inhibitor, is a deuterated form of momelotinib and has shown promising results for treating patients with myelofibrosis (MF), specifically in spleen volume reduction and symptom relief.
Here, we summarize a long-term follow-up of the ZGJAK002 trial (NCT03886415) published by Zhang et al.1 in American Journal of Hematology assessing the safety and efficacy of jaktinib in Chinese patients with intermediate to high-risk MF.
Table 1. Key long-term efficacy and safety data for jaktinib 100 mg BID and 200 mg QD regimens*
Figure 1. SVR35 in patients with intermediate to high-risk MF treated with 100 mg BID or 200 mg QD jaktinib*
BID, twice daily; MF, myelofibrosis; QD, once daily; SVR35, spleen volume reduction ≥35%.
*Adapted from Zhang, et al.1
Key learnings |
---|
|
Your opinion matters
Subscribe to get the best content related to MPN delivered to your inbox